Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Switch OTC Versions of Pemirolast K Recommended for Approval
August 29, 2011
- BI Licenses ADCC Enhancing Technology from ProBioGen
August 29, 2011
- Caffeine Citrate Designated as an Orphan Drug
August 29, 2011
- JAMS Opposes Switch OTC Status for 3 Drugs Including Acarbose
August 29, 2011
- Eisai Establishes Marketing Subsidiary in Mexico
August 29, 2011
- JGA to Ask for Retention of “70% Rule”in Pricing of “First Generics”
August 29, 2011
- Mr Wolf of PhRMA Explains Advantages of VICP Introduced in US
August 29, 2011
- Shionogi Acquires 24.17% Stake in C&O of China
August 29, 2011
- Kyowa Pharm. Ind. Seeking M&A to Expand Product Line-up
August 29, 2011
- Saitama Police Send Case to Public Prosecutors Office against President of Saitama Pharm. Association
August 29, 2011
- US Court Orders Actelion to Pay Damages to Asahi Kasei Pharma for Stopping Fasudil's Development
August 29, 2011
- Biosimilars Offer Growth Opportunity: President Sakamoto of Toyobo
August 29, 2011
- Revlimid Offers Great Convenience: Dr Hatake of Cancer Institute Hospital
August 29, 2011
- US Court of Appeals Rules for MTPC in Argatroban Patent Dispute
August 29, 2011
- No. of Health Insurance Societies That Report Savings by Generics to Insured More Than Triples: Kenporen
August 29, 2011
- Launching of Novel Anticoagulants Welcomed: JCS Symposium
August 29, 2011
- Radioactive Cesium Detected from RDF Incineration Ashes at Chugai's Research Lab
August 29, 2011
- St. Marianna Univ. Hospital Group Saves over ¥600 Mil. in Drug Expenditures by Using Generics
August 29, 2011
- Takeda to Increase No. of MRs to 2,000 in China
August 29, 2011
- Concrete Disclosure Standards Should Have Been Included in JPMA's GLs for COI: Prof. Miyata
August 29, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…